SCHEMBL5746037

SCHEMBL5746037

CCN1c2ncc(Br)cc2C(=O)N(C)c2ccc(C)nc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.44
CYP2C9 P11712 5/20 0.44
CYP2C19 P33261 5/20 0.44
CYP1A2 P05177 3/20 0.44
CYP1B1 Q16678 1/20 0.36
CYP2D6 P10635 2/20 0.33
ALDH1A1 P00352 2/20 0.33
TSHR P16473 1/20 0.33
LRRK2 Q5S007 2/20 0.33
DCLK1 O15075 1/20 0.33
MAPK7 Q13164 1/20 0.33
RXFP1 Q9HBX9 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRA6 Q16445 1/20 0.32
CUL4A Q13619 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5745671 0.87 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19CYP1A2CYP1B1
SCHEMBL6964112 0.87 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19CYP1A2CYP1B1
SCHEMBL4035380 0.87 CYP3A4 (0.54) CYP3A4CYP2C9CYP2C19CYP1A2CYP1B1
SCHEMBL5744876 0.84 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19CYP1A2CYP1B1
SCHEMBL5745003 0.82 CYP3A4 (0.53) CYP3A4CYP2C9CYP2C19CYP1A2CYP1B1
SCHEMBL5743651 0.82 CYP3A4 (0.54) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL5745579 0.81 CYP3A4 (0.49) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL17878840 0.76 DRD2 (0.47) CYP1B1ALDH1A1LRRK2DCLK1MAPK7
SCHEMBL6964250 0.76 CYP3A4 (0.35) CYP3A4CYP2C9CYP2C19CYP1A2CYP1B1
SCHEMBL6960855 0.73 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655300-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2006-05-10 EP disclosed
EP-1294720-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM CA LTD (CA) 2006-04-05 EP disclosed
US-6420359-B1 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-07-16 US disclosed
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors REV1, POLR2H, POLR2E CYP3A4 560/4885CYP2C9 1933/4885CYP2C19 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.